Ultragenyx Q3 2026 net loss narrows 34% to $118 million

Bitget2026/11/03 21:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ultragenyx narrowed its third-quarter 2026 net loss 34% year over year to $118 million, while revenue rose 8% to $173 million.
Operating expenses fell 15% year over year to $283 million, while research and development spending dropped 29% to $154 million.
Planned headcount cuts total approximately 20%, with 2027 research and development expenses expected below $350 million.
GENGLYCOS and FAYUVI received FDA approval in the third quarter, marking the company's first gene therapy approvals.
Full-year 2026 revenue guidance remains $730 million–$760 million, excluding new product launches; full-year GAAP profitability remains expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611031601PRIMZONEFULLFEED9869518) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ultragenyx Q3 2026 net loss narrows 34% to $118 million

You may also like

Crypto prices